Elite Pharmaceuticals Reports Quarterly Earnings

Specialty drugmaker posts $0.01 earnings per share in latest quarter

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Elite Pharmaceuticals (OTCMKTS:ELTP), a specialty pharmaceutical company focused on complex drug formulations, has reported its latest quarterly earnings results. The company posted earnings per share of $0.01 for the quarter, with a net margin of 11.33% and a negative return on equity of 0.72%.

Why it matters

Elite Pharmaceuticals is a small but growing player in the specialty pharmaceutical space, developing complex drug products like injectables and oncology therapies. Its latest earnings report provides insight into the company's financial performance and operational progress as it seeks to expand its portfolio and manufacturing capabilities through strategic partnerships.

The details

In its quarterly report, Elite Pharmaceuticals reported earnings per share of $0.01, in line with analyst expectations. The company's net margin was 11.33% and it had a negative return on equity of 0.72%. Elite Pharmaceuticals is headquartered in Houston, Texas and focuses on acquiring, developing and marketing both branded and generic pharmaceutical products.

  • Elite Pharmaceuticals released its quarterly earnings results on Tuesday, February 17, 2026.

The players

Elite Pharmaceuticals

A U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products, with a focus on complex dosage forms like injectables and oncology therapies.

Got photos? Submit your photos here. ›

The takeaway

Elite Pharmaceuticals' latest earnings report demonstrates the company's ability to generate modest profitability as it continues to build out its portfolio of specialty pharmaceutical products. However, the company's negative return on equity suggests it still has work to do in optimizing its operations and driving stronger financial performance.